(Q46416422)

22 December 2017

title

Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma (English)

1 reference

22 December 2017

0 references

1

1 reference

22 December 2017

author name string

Ronald M Bukowski

2

1 reference

22 December 2017

Robert A Figlin

3

1 reference

22 December 2017

Thomas E Hutson

4

1 reference

22 December 2017

M Dror Michaelson

5

1 reference

22 December 2017

Sindy T Kim

6

1 reference

22 December 2017

Charles M Baum

7

1 reference

22 December 2017

Michael W Kattan

8

1 reference

22 December 2017

language of work or name

English

0 references

publication date

1 October 2008

1 reference

22 December 2017

published in

Cancer

1 reference

22 December 2017

volume

113

1 reference

22 December 2017

page(s)

1552-1558

1 reference

22 December 2017

issue

7

1 reference

22 December 2017

Sunitinib: from rational design to clinical efficacy

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23776

7 January 2021

Genetic basis of cancer of the kidney: disease-specific approaches to therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23776

7 January 2021

Targeting von Hippel-Lindau pathway in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23776

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23776

7 January 2021

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23776

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23776

7 January 2021

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23776

7 January 2021

Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23776

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23776

7 January 2021

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23776

7 January 2021

Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23776

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23776

7 January 2021

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23776

7 January 2021

Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23776

7 January 2021

Postoperative nomogram for 12-year sarcoma-specific death

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23776

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23776

7 January 2021

Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23776

7 January 2021

Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23776

7 January 2021

Evaluating the yield of medical tests

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23776

7 January 2021

Albumin as an aid to the interpretation of serum calcium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23776

7 January 2021

Targeted therapy for metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23776

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23776

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23776

7 January 2021

Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23776

7 January 2021

Identifiers

DOI

10.1002/CNCR.23776

1 reference

22 December 2017

PubMed ID

18720362

1 reference

22 December 2017